BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibitor Brukinsa Plus Rituximab In Adult Pat
BeOne Medicines Ltd. (NASDAQ: ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult p